BSX as reported
Boston Scientific reported $21.0B of revenue over the trailing twelve months, +14% on the year before. 11 reported series are charted on this page, each one as filed.
$21.0B
Revenue, trailing twelve months · to Q2 2026 · +14% against the twelve months before
- Net Income
- $3.67B
Net Income · +47% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $3.63B
Free Cash Flow · +4.0% year on year · trailing twelve months to Q2 2026
- Op Margin
- 20%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $21.0B | +14% | Q2 2026 |
| Net Income | $3.67B | +47% | Q2 2026 |
| EPS | $2.47 | +47% | Q2 2026 |
| Gross Margin | 70% | n/a | Q2 2026 |
| Op Margin | 20% | n/a | Q2 2026 |
| Net Margin | 17% | n/a | Q2 2026 |
| ROE | 13% | n/a | Q2 2026 |
| ROA | 7.3% | n/a | Q2 2026 |
| ROIC | 8.4% | n/a | Q2 2026 |
| Free Cash Flow | $3.63B | +4.0% | Q2 2026 |
| P/E | 19.5 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Boston Scientific (BSX) - Revenue & ProfitRevenue & ProfitBoston Scientific (BSX)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Medical Devices
Ranks #24 of 35 by Smart Score